Pages that link to "Q28394341"
Jump to navigation
Jump to search
The following pages link to Dopamine Targeting Drugs for the Treatment of Schizophrenia: Past, Present and Future (Q28394341):
Displayed 22 items.
- Dysbindin-1 Involvement in the Etiology of Schizophrenia. (Q46387449) (← links)
- mir-193 targets ALDH2 and contributes to toxic aldehyde accumulation and tyrosine hydroxylase dysfunction in cerebral ischemia/reperfusion injury (Q47094072) (← links)
- Adherence, persistence, and inpatient utilization among adult schizophrenia patients using once-monthly versus twice-monthly long-acting atypical antipsychotics (Q47998008) (← links)
- Synthesis, radiolabelling, and evaluation of [11C]PB212 as a radioligand for imaging sigma-1 receptors using PET. (Q51741015) (← links)
- Regulation of cortical and peripheral GCH1 expression and biopterin levels in schizophrenia-spectrum disorders. (Q51767888) (← links)
- Psychosis as an Evolutionary Adaptive Mechanism to Changing Environments. (Q55293266) (← links)
- Two eARCHT3.0 Lines for Optogenetic Silencing of Dopaminergic and Serotonergic Neurons (Q61803796) (← links)
- Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus (Q64786636) (← links)
- The therapeutic potential of metabotropic glutamate receptor modulation for schizophrenia (Q87897513) (← links)
- Effect of chemogenetic actuator drugs on prefrontal cortex-dependent working memory in nonhuman primates (Q90472038) (← links)
- Synthesis and Biological Evaluation of Five-Atom-Linker-Based Arylpiperazine Derivatives with an Atypical Antipsychotic Profile (Q91352132) (← links)
- The effect of aripiprazole once-monthly on personal and social functioning: post hoc analyses of acute and long-term studies (Q91810549) (← links)
- A quantum chemical approach representing a new perspective concerning agonist and antagonist drugs in the context of schizophrenia and Parkinson's disease (Q91917397) (← links)
- The Cross-Talk Between the Dopaminergic and the Immune System Involved in Schizophrenia (Q91972968) (← links)
- Evaluation of α-synuclein and apolipoprotein E as potential biomarkers in cerebrospinal fluid to monitor pharmacotherapeutic efficacy in dopamine dictated disease states of Parkinson's disease and schizophrenia (Q92603890) (← links)
- Treatment-Resistant Schizophrenia: Insights From Genetic Studies and Machine Learning Approaches (Q92699288) (← links)
- Assessing the Structural and Pharmacological Similarity of Newly Identified Drugs of Abuse to Controlled Substances Using Public Health Assessment via Structural Evaluation (Q92921262) (← links)
- Clozapine versus olanzapine for people with schizophrenia (Q94400577) (← links)
- Clozapine versus quetiapine for people with schizophrenia (Q94400921) (← links)
- Clozapine versus risperidone for people with schizophrenia (Q94401224) (← links)
- Neuronal defects in a human cellular model of 22q11.2 deletion syndrome (Q100316498) (← links)
- MDMA-induced changes in within-network connectivity contradict the specificity of these alterations for the effects of serotonergic hallucinogens (Q102220405) (← links)